# Developing Scientific Research Proposals (Grant Writing)

2003 Epidemiology and Biostatistics Summer Session



Alan Kristal, Dr.P.H.

**Session 7** 


Statistical Power


## **Power**


#### **Purpose**

- Demonstrate that at the completion of data collection there will be sufficient numbers of observations to test <u>primary</u> specific aims.
- Recommended reference: Kelsey JL, Whittmore AS, Evans AS, Thompson WD. Methods in Observational Epidemiology. Oxford University Press, 2<sup>nd</sup> ed. 1996

. . . . . . . .







**Components of Statistical Power** Power is a function of four parameters · Effect size · Sample size Probability of a non-significant test when H<sub>o</sub> should be rejected (β error) - Probability of a significant test when  ${\rm H}_{\rm o}$  should not be rejected (α error) **Components of Statistical Power Effect Size**  Magnitude of intervention effect · Relative risk · Odds ratio · Hazard ratio • Shared variance (correlation or regression) **Components of Statistical Power** Sample size Number of cases and controls (case/control study) • Number of participants (cohort, experiment)

**Components of Statistical Power** Probability of significant test when Ho should not be rejected Alpha error (α) · One sided vs. two sided **Components of Statistical Power** Probability of non-significant test when H<sub>o</sub> should be rejected Beta error (β) • Power = 1-  $\beta$ **Describing Power** Alpha error is almost always set at 0.05 (two sided). Thus, power sections usually take one of the following three approaches: 1. Solve for minimally detectable effect size

2. Solve for number of study participants

3. Solve for power

## **Describing Power**

#### Solve for minimally detectable effect size

- You have a limited number of participants available for study. For example, cases of newly diagnosed breast cancer in King County.
- · You set power at 80%.
- · What relative risk could you detect.

0

## **Power Table - Fixed Sample Size**

Minimally Detectable Effect in Nested Case-Cohort Analysis

Specific Aims	Title	Cases (n)	Cohort or Controls (n)	Minimal Detectable RR
Specific Aim1 (a), (b) and 2 (a) and (b)	Diet and Prostate Cancer	700	1400	0.70
Specific Aim 1 (c)	Serum Fatty Acids and Prostate Cancer	700	1400	0.40
Specific Aim A.2 (c)			1400	0.60

0

## **Describing Power**

#### Solve for number of participants

- You know or hypothesize an effect size. For example, you determine that a 25% reduction in risk is worth detecting.
- · You set power at 90%.
- · How many participants do you need?

. . . . . . . .

	_
	_
	_
	_
	_
 <u> </u>	
 	_
	_
	_
	_
	_
	_
	_
	_
	_

0

## **Power Table - Intervention Trial**

#### Trial of Behavioral Intervention for Dietary Change

Instrument	Measure	Smallest Meaningful Intervention Effect Between Arms	Power (1-B)	Minimum Detectable Difference with 90% Power
Principal Endpoints				
24-Hour Diet Recall	Fat (% En)	2 percentage points	.90	2.0
	Fiber (g/ 1000 Kcal)	2 g	>.95	1.8
		0 0 0		

0

## **Power Table - Intervention Trial**

#### Trial of Behavioral Intervention for Dietary Change

Secondary Endpoints         Fat Scale         0.14 units         > .95         .057           Fat and Fiber Behavior (FFB)         Fiber Scale         0.19 units         > .95         .064           Stage of Change         Percent moving into action stage         Fat: 18 percentage points Fiber: 17 percentage points         .94         .14           > .95         .11         > .95         .11	Instrument	Measure	Smallest Meaningful Intervention Effect Between Arms	Power (1-B)	Minimum Detectable Difference 90% Power
Behavior					
Change moving into percentage points action stage Fiber: 17 > .95 .11	Behavior				
	Stage of Percent Change moving into		percentage points Fiber: 17		

0 0 0 0 0 0

0

## **Describing Power**

#### Solve for power

- You have a limited number of participants available.
- You declare a minimally detectable effect size.
- How much power would have to detect effect sizes at least this large?

0 0 0 0 0 0

#### **Power Table - Power to Detect Effects**

Case-Control Study of Medication Use and Prostate Cancer Risk

Odds ratio	Prevalence of exposure among controls					
[	0.05	0.10	0.15	0.20	0.30	0.40
0.5	0.79	0.98	>.99	>.99	>.99	>.99
0.6	0.56	0.85	0.95	>.99	>.99	>.99
0.7	0.32	0.57	0.74	0.84	0.93	0.96
0.8	0.15	0.27	0.38	0.46	0.59	0.66
1.3	0.24	0.43	0.57	0.66	0.77	0.82
1.4	0.39	0.65	0.80	0.87	0.94	0.96
1.5	0.54	0.82	0.93	0.97	0.99	0.99
1.8	0.89	0.99	>.99	>.99	>.99	>.99
2.0	0.07	> 00	> 00	> 00	> 00	> 00

\* Based on a total sample size of 1000 cases, 1000 controls; alpha=0.05, 2-tailed.

**Estimating Effect Size** 

- Decreased incidence in treatment vs. placebo study arm
- Difference in incidence in persons exposed vs. not exposed
- Relative risks/odds ratios comparing persons in highest to lowest exposure category

• • • • • • •

## **Estimating Effect Size**

How to determine effect size (in order or preference)

- Pilot study
- · Clinically meaningful
- · Significant at population level
- · By analogy to similar exposure to similar disease
- Ideology (standards in one's field)

۰		
	_	
۰		

**Assumptions for Power Calculations Cohort Studies** · Incidence rate · Proportion of population exposed · Variability of exposure in population **Assumptions for Power Calculations Case-Control Studies** · Number of Cases and Controls · Matched vs. unmatched analyses · Proportion of exposed controls **Assumptions for Power Calculations Intervention Trials** • Adherence · Drop-out • Drop-in · Incidence rate in contrast (untreated) group

## **How Much Power is Enough?**

- For observation studies, try to achieve at least 80% power (1-β), with two-sided alpha error at 5% (p<0.05).</li>
- For experiments with disease outcomes, try to achieve 90% power with two-sided alpha error at 5%.

## **How Much Power is Enough?**

 For experiments with non-disease outcomes, balance costs and societal importance. Is the cost of an effect not detected due to low power more the cost of increasing sample size?

# **Alpha-Error and Multiple Testing**

- · Do not ignore!
- Adjust α if feasible (especially for intervention trial with multiple endpoints)
- Site a-priori hypotheses as those not needing protection from multiple testing
- Move as many tests to secondary aims as possible (power less critical for secondary aims)


# **Methods - Common Criticisms** Design · Lack of adequate control group · Inadequate rationale for selection of control or comparison group · Model not appropriate for hypothesis **Methods - Common Criticisms Participants** · Population not representative · Insufficient evidence for recruiting sufficient numbers · Overly optimistic estimates of participation, adherence, or drop out **Methods - Common Criticisms Assessments** · Measures not validated · Over-reliance on self-report · Unrealistic participant burden · Fishing expedition • Data collection protocol not comparable across

time or study groups

**Methods - Common Criticisms** Intervention · No conceptual framework · No pilot data on efficacy · Too complex · Unrealistic participant burden · Differential attrition across study arms Dangerous **Methods - Common Criticisms Treatment Trials** · Treatment not blinded · Inadequate or no assessment of compliance · Dose/protocol not justified · No control for contamination/drop-ins **Methods-Common Criticisms** Data analysis • Power estimates missing for primary specific aims · Analysis plan does not match study design · Analysis proposed but not described • Analysis plan is vague - not clear how hypotheses will tested